NCT03533452

Brief Summary

Arthroscopic rotator cuff surgery of the shoulder is performed under general anesthesia. Pain control for after the surgery can be achieved purely with intravenous and oral pain medication or in combination with freezing of the nerves. Nerve freezing (nerve block) placed before surgery has the potential to substantially reduce the amount of inhaled anesthetic given to the patient during surgery. This can benefit the patient by minimizing the opioid usage after surgery and also reduce cost to the system in terms of duration of hospital stay. The purpose of the study is to investigate whether the inclusion of a nerve block to the general anesthetic for rotator cuff repair surgery will also reduce the amount of inhaled anesthetic and thereby lowering the environmental footprint from the anesthetic. The investigators of the proposed study plan to quantify the amount of inhaled anesthetic used for each case and will compare how the consumption is affected by whether the nerve block is applied before or after surgery. Patients will have a nerve block catheter (interscalene catheter) placed under ultrasound-guidance prior to the induction of general anesthetic by an experienced regional anesthesiologist. The nerve block catheter will be bolused with a solution to which the anesthesiologist is blinded which will either be local anesthetic or normal saline (sham). The general anesthetic will be conducted according to a the protocol with the aim of maintaining a standard anesthetic depth monitored by patient state index (PSI). Measurements of the MAC-Value (minimum alveolar concentration) of inhaled anesthetic will be recorded every five minutes and the total amount of volatile anesthetic (in ml and ml/kg) will be noted down by a blinded observer. At the end of the case the anesthesiologist blinded to the solution will inject another solution (now a saline (sham) or local anesthetic before the patient is woken up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started May 2019

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 23, 2018

Completed
11 months until next milestone

Study Start

First participant enrolled

May 1, 2019

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

May 24, 2022

Status Verified

May 1, 2022

Enrollment Period

2.7 years

First QC Date

April 9, 2018

Last Update Submit

May 23, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Average age-adjusted MAC of sevoflurane

    The average age-adjusted end- tidal minimum alveolar concentration (MAC) will be calculated by averaging the end tidal MAC required to maintain the depth of anesthesia as measured by PSI between 25-50 intra-operatively. This will be compared between the two groups.

    Intra-operative measurement done at the end of anesthetic

Secondary Outcomes (11)

  • Sevoflurane consumption in ml/hr

    Intra-operative - measurement done at the end of anesthetic

  • Sevoflurane consumption in ml//kg/hr

    Intra-operative - measurement done at the end of anesthetic

  • Intraoperative hemodynamics

    Intraoperative period

  • Intraoperative opioid use

    Intraoperative period

  • Postoperative opioid use in PACU

    24 postoperative hours

  • +6 more secondary outcomes

Study Arms (2)

PRE-GA

ACTIVE COMPARATOR

10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter

Drug: RopivacaineDrug: Normal saline

POST-GA

SHAM COMPARATOR

10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter

Drug: RopivacaineDrug: Normal saline

Interventions

Local anesthetic injection

POST-GAPRE-GA

Sham injection

POST-GAPRE-GA

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective shoulder arthroscopy
  • Patients eligible for interscalene brachial plexus block
  • All adults \> 18 years of age
  • Capable to give consent

You may not qualify if:

  • Patients who are unable to give consent
  • Local anaesthetic allergy
  • Hemidiaphragm paresis on the contralateral side to the block/surgery site
  • Bleeding diathesis
  • Coagulopathy
  • Pre-existing neurological deficits
  • Patients with a Body Mass Index \>35
  • Patients with significant comorbidities, physiological limitations, and allergies that are unable to tolerate the protocolized induction and maintenance of anesthesia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Alberta Hospital

Edmonton, Alberta, T6G2G3, Canada

Location

Sturgeon Community Hospital

St. Albert, Alberta, T8N6C4, Canada

Location

MeSH Terms

Conditions

Rotator Cuff Injuries

Interventions

RopivacaineSaline Solution

Condition Hierarchy (Ancestors)

RuptureWounds and InjuriesShoulder InjuriesTendon Injuries

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Vivian HY Ip, MD

    University of Alberta

    STUDY DIRECTOR
  • Timur JP Özelsel, MD

    University of Alberta

    PRINCIPAL INVESTIGATOR
  • Rakesh V Sondekoppam, MD

    University of Alberta

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Double-blinded, randomized controlled, prospective
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2018

First Posted

May 23, 2018

Study Start

May 1, 2019

Primary Completion

January 1, 2022

Study Completion

January 1, 2022

Last Updated

May 24, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations